Click on the panels below to find out more about our latest hosted content
An award winning1 design containing the effective combination of drugs you know.
Learn how Integrated Health Solutions, the services and solutions division of Medtronic, partners with healthcare providers to optimise cost and outcomes.
Using the NICE guidelines to manage frequent infant regurgitation with marked distress Based on NICE guidelines [NG1], January 2015¹
A survey of 710 people with rosacea and 554 doctors has revealed valuable insights on the invisible impact of a visible disease for the patients and the community. It is time to fight back against stereotypes and talk openly about rosacea burden.
Find out more about how we can reduce the burden of eczema for patients, GPs and the NHS
Find out more about the latest Pfizer Anti-Infectives offerings
PP-ZVA-GBR-0479
August 2018
Information intended for UK healthcare professionals only
Promotional information on Pradaxa® (dabigatran etexilate) for stroke prevention in patients with non-valvular atrial fibrillation. This webpage is intended for UK Healthcare Professionals interested in stroke prevention in non-valvular atrial fibrillation. PC-UK-101343 V1 June 2019
This resource is intended for UK healthcare professionals only and provides information on the management of patients with inflammatory bowel disease or listed for surgery.• How to meet the full iron need of inflammatory bowel disease patients with iron deficiency anaemia.• Meeting the challenges of perioperative anaemia.Job code: UK-MONF-0918-00023Date of preparation: September 2018
The more targetable genes are identified and treatment choice grows, the more clinical practice is shifting towards an era of precision medicine. Being aware of this, Roche is collaborating with molecular insights leader Foundation Medicine
Don’t let psoriasis or psoriatic arthritis hold your patients back.Help your patients move forward with OTEZLA®.
This resource provides information on the management of patients with adult ADHD.Job code: C-APROM/UK//2853Date of prep: May 2019Initiated and funded by Takeda Pharmaceuticals Limited.
Click here to read more about Jazz Pharmaceuticals’ treatment for adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)EURW-UKVYX-0084 | May 2019Please note this site is intended for Healthcare Professionals Only.